Residency · Scottsdale, AZ
Sponsored by HonorHealth
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2023 · 110 citations · Michael Manning
Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
The New England journal of medicine · 2024 · 65 citations · Michael Manning
Exploring the role of telehealth in providing equitable healthcare to the vulnerable patient population during COVID-19.
Journal of telemedicine and telecare · 2024 · 32 citations · Dania Shah, Dana Sall, Rustan Sharer, Priya Radhakrishnan
Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions.
Journal of clinical medicine · 2025 · 21 citations · Harshad Chaudhari
The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024 · 19 citations ·
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study.
Advances in therapy · 2025 · 14 citations · Michael Manning
Inhibition of Prekallikrein for Hereditary Angioedema.
The New England journal of medicine · 2022 · 61 citations · Michael Manning
A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
Allergy · 2024 · 21 citations · Michael Manning